カテゴリ： Allied Market Research, 世界, 医療/バイオ

胃腸治療薬の世界市場2023-2032：機会分析・産業予測

■ 英語タイトル：Gastrointestinal Therapeutics Market By Drug Class (Biologics, Proton Pump Inhibitors, Aminosalicylates, Antacids, Laxatives, H2 Antagonists, Others), By Application (Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23OCT095）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23OCT095
■ 発行日：2023年8月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：320
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[胃腸治療薬の世界市場2023-2032：機会分析・産業予測]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

胃腸治療薬市場は2022年に395億ドルと評価され、2023年から2032年までの年平均成長率は5.0%で、2032年には645億ドルに達すると予測されています。
胃腸治療学は、消化管（GI）に影響を及ぼす障害や疾患の診断、治療、管理に焦点を当てた医学と医療の一分野を指します。消化管は、食物の消化・吸収と老廃物の排泄を担う複雑なシステムです。消化管には、口、食道、胃、小腸、大腸、直腸、肛門などの器官が含まれます。消化器治療薬には、制酸薬、プロトンポンプ阻害薬、制吐薬、下剤、鎮痙薬、抗炎症薬、免疫抑制薬などがあります。

消化器病学、免疫学、微生物学などの分野で進められている研究は、消化器疾患の根本的な原因やメカニズムの理解を深めることに貢献しています。この知識は、標的療法やより個別化された治療アプローチの開発につながります。胃腸治療薬市場は、胃食道逆流症（GERD）、炎症性腸疾患（IBD）、過敏性腸症候群（IBS）などの胃腸疾患の有病率の上昇により、大きな成長を遂げています。例えば、2022年のアメリカ生物工学情報センター（NCBI）によると、胃食道逆流症（GERD）はアメリカで最も多く診断される消化器疾患の一つであり、有病率は20％で、直接的および間接的なコストにおいて大きな経済的負担をもたらします。これらの疾患は世界中で何百万人もの人々に影響を及ぼしているため、効果的な治療オプションに対する需要が急増しており、市場成長の原動力になると期待されています。

さらに、生物学的製剤の開発が消化器疾患の治療状況に革命をもたらし、市場の成長をさらに後押ししています。モノクローナル抗体やサイトカイン阻害剤などの生物学的製剤は、クローン病や潰瘍性大腸炎などの疾患に関連する炎症プロセスを修正する標的介入を提供します。さらに、胃腸治療薬の分野で進行中の研究開発活動は、市場の成長に貢献しています。製薬会社、学術機関、研究機関は、革新的な治療法の発見と開発、治療効果の向上、利用可能な胃腸治療薬の範囲の拡大に投資しています。例えば、Inspirna, Inc.は、RGX-202-01（Ompenaclid）の2nd Line RAS遺伝子変異進行大腸がん併用療法としての第1相試験を実施中です。このように、胃腸治療薬の分野で進行中の研究開発活動の増加は、市場の成長を促進すると予想されます。

胃腸治療薬市場は、薬剤クラス、用途、流通チャネル、地域に区分されます。
薬剤クラス別では、生物学的製剤、プロトンポンプ阻害薬、アミノサリチル酸塩、制酸薬、緩下剤、H2拮抗薬、その他に分類されます。
用途別では、市場は炎症性腸疾患、胃食道逆流症、消化性潰瘍疾患、過敏性腸症候群、その他に分類されます。炎症性腸疾患セグメントはさらにクローン病と潰瘍性大腸炎に分類されます。消化性潰瘍疾患セグメントはさらに胃潰瘍と十二指腸潰瘍に分類されます。
流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されています。地域別では、北米（アメリカ、カナダ、メキシコ）、ヨーロッパ（ドイツ、フランス、イギリス、イタリア、スペイン、その他ヨーロッパ）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、中南米・中東・アフリカ（ブラジル、サウジアラビア、南アフリカ、その他）にわたって分析しています。
胃腸治療薬市場で事業を展開する主な主要企業は、AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company.などが含まれます。主要企業は、胃腸治療薬市場の製品ポートフォリオを改善するための主要な開発戦略として、製品上市、製品承認、臨床試験を採用しています。

ステークホルダーにとっての主な利点
当レポートでは、2022年から2032年までの胃腸治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、胃腸治療薬市場の優勢な機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
胃腸治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
胃腸治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録しています。

本レポートをご購入いただくと、以下の特典があります：
四半期ごとの更新可能です*（コーポレート・ライセンスの場合のみ、表示価格でのご提供となります）
無料のアップデートとして、購入前または購入後に、5社の会社概要を追加可能です。
アナリストによる16時間のサポート可能です。* (購入後、レポートのレビューで追加のデータ要件が見つかった場合、質問や販売後の問い合わせを解決するためにアナリストによる16時間のサポートを受けることができます)
15% の無料カスタマイズ可能です。* （レポートの範囲またはセグメントが要件と一致しない場合、20% は 3 営業日の無料作業に相当し、1 回適用されます。）
5ユーザー・エンタープライズユーザーライセンスの無料データパック可能です。(Excel版レポート）
レポートが6～12ヶ月以上前の場合、無料更新可能です。
24時間優先対応可能です。
産業の最新情報とホワイトペーパーを無料で提供します。

本レポートで可能なカスタマイズ（追加費用とスケジュールが必要です。）
規制ガイドライン
クライアントの関心に特化した追加企業プロファイル
国または地域の追加分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなど、エクセル形式を含む）

主要市場セグメント

薬剤クラス別
生物製剤
プロトンポンプ阻害薬
アミノサリチル酸塩
制酸剤
下剤
H2拮抗薬
その他

用途別
炎症性腸疾患治療剤
タイプ
クローン病
潰瘍性大腸炎
胃食道逆流症
消化性潰瘍性疾患
タイプ
胃潰瘍
十二指腸潰瘍
過敏性腸症候群
その他

流通チャネル別
病院薬局
ドラッグストア・小売薬局
オンラインプロバイダー

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
中南米・中東・アフリカ
ブラジル
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
Bayer AG
Bausch Health Companies Inc.
Cosmo Pharmaceuticals
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
AbbVie Inc.
Organon Group of Companies
Pfizer Inc.
AstraZeneca plc
Bristol-Myers Squibb Company

第1章. 序章
第2章. エグゼクティブサマリー
第3章. 市場概要
第4章. 胃腸治療薬の市場分析：薬物クラス別
第5章. 胃腸治療薬の市場分析：用途別
第6章. 胃腸治療薬の市場分析：流通チャネル別
第7章. 胃腸治療薬の市場分析：地域別
第8章. 競争状況
第9章. 企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of gastrointestinal diseases
3.4.1.2. Rise in geriatric population
3.4.1.3. Rise in number of product launches

3.4.2. Restraints
3.4.2.1. Stringent government regulations toward approval of biosimilars
3.4.2.2. Patent expiry of drugs

3.4.3. Opportunities
3.4.3.1. Rise in R&D activities
3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Biologics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Proton Pump Inhibitors
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Aminosalicylates
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Antacids
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Laxatives
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.7. H2 Antagonists
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
4.8. Others
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market share analysis by country
CHAPTER 5: GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Inflammatory Bowel Disease
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Inflammatory Bowel Disease Gastrointestinal Therapeutics Market by Type
5.3. Gastroesophageal Reflux Disease
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Peptic Ulcer Disease
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.4.4. Peptic Ulcer Disease Gastrointestinal Therapeutics Market by Type
5.5. Irritable Bowel Syndrome
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug Class
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug Class
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug Class
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug Class
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug Class
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug Class
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug Class
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug Class
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug Class
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Drug Class
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Drug Class
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Drug Class
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Drug Class
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Drug Class
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Drug Class
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug Class
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Drug Class
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Drug Class
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Drug Class
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. AbbVie Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. AstraZeneca plc
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Pfizer Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Bayer AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Bausch Health Companies Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Takeda Pharmaceutical Company Limited
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Cosmo Pharmaceuticals
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Organon Group of Companies
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Bristol-Myers Squibb Company
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Teva Pharmaceutical Industries Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. GASTROINTESTINAL THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GASTROINTESTINAL THERAPEUTICS MARKET FOR PROTON PUMP INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GASTROINTESTINAL THERAPEUTICS MARKET FOR AMINOSALICYLATES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GASTROINTESTINAL THERAPEUTICS MARKET FOR ANTACIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GASTROINTESTINAL THERAPEUTICS MARKET FOR LAXATIVES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GASTROINTESTINAL THERAPEUTICS MARKET FOR H2 ANTAGONISTS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 10. GASTROINTESTINAL THERAPEUTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE GASTROINTESTINAL THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 12. GASTROINTESTINAL THERAPEUTICS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GASTROINTESTINAL THERAPEUTICS MARKET FOR PEPTIC ULCER DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL PEPTIC ULCER DISEASE GASTROINTESTINAL THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 15. GASTROINTESTINAL THERAPEUTICS MARKET FOR IRRITABLE BOWEL SYNDROME, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. GASTROINTESTINAL THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 19. GASTROINTESTINAL THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 20. GASTROINTESTINAL THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 26. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 27. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 30. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 33. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 36. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 39. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 40. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 43. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 46. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 49. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 52. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 55. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 58. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 61. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 62. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 65. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 68. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 71. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 74. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 77. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 80. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 83. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 84. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 87. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 90. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 91. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 92. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 93. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 94. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 95. ABBVIE INC.: KEY EXECUTIVES
TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 99. ABBVIE INC.: KEY STRATERGIES
TABLE 100. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 101. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 102. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 103. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 104. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 105. PFIZER INC.: KEY EXECUTIVES
TABLE 106. PFIZER INC.: COMPANY SNAPSHOT
TABLE 107. PFIZER INC.: PRODUCT SEGMENTS
TABLE 108. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 109. BAYER AG: KEY EXECUTIVES
TABLE 110. BAYER AG: COMPANY SNAPSHOT
TABLE 111. BAYER AG: PRODUCT SEGMENTS
TABLE 112. BAYER AG: PRODUCT PORTFOLIO
TABLE 113. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 114. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 115. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 116. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 119. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
TABLE 120. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 121. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
TABLE 122. COSMO PHARMACEUTICALS: KEY EXECUTIVES
TABLE 123. COSMO PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 124. COSMO PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 125. COSMO PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 126. ORGANON GROUP OF COMPANIES: KEY EXECUTIVES
TABLE 127. ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT
TABLE 128. ORGANON GROUP OF COMPANIES: PRODUCT SEGMENTS
TABLE 129. ORGANON GROUP OF COMPANIES: PRODUCT PORTFOLIO
TABLE 130. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 131. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 132. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 133. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 134. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 137. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 138. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 139. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗血小板剤の世界市場2023-2032：機会分析・産業予測
  • 経口抗生物質の世界市場2023-2032：機会分析・産業予測
  • 抗菌薬耐性の世界市場2023-2032：機会分析・産業予測
  • 自動車用音声認識システムの世界市場2023-2032：機会分析・産業予測
  • 自動車用外装ドアハンドルの世界市場2023-2032：機会分析・産業予測
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23OCT095 )"胃腸治療薬の世界市場2023-2032：機会分析・産業予測" (英文：Gastrointestinal Therapeutics Market By Drug Class (Biologics, Proton Pump Inhibitors, Aminosalicylates, Antacids, Laxatives, H2 Antagonists, Others), By Application (Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。